Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
NCT06326411 · View on ClinicalTrials.gov ↗
Study Summary
This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.
Conditions Studied
Interventions
- DRUG NST-628
Study Locations (20)
New York
- Roswell Park — Buffalo
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health — New York
- Columbia University Medical Center — New York
- Memorial Slone Kettering Cancer Center — New York
Texas
- NEXT Oncology - Austin — Austin
- NEXT Oncology - Dallas — Dallas
- MD Anderson Cancer Center — Houston
California
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco
- UCLA Hematology/Oncology — Westwood, Los Angeles
Tennessee
- SCRI Oncology Partners — Nashville
- Vanderbilt-Ingram Cancer Center — Nashville
New South Wales
- The Kinghorn Cancer Center, St. Vincent's Health Network — Darlinghurst
- Scientia Clinical Research, Ltd — Randwick
Colorado
- Sarah Cannon Research Institute at Health ONE — Denver
Connecticut
- Yale Cancer Center — New Haven
Florida
- Moffitt Cancer Center — Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2024-04-09 |
| Est. Completion | 2029-11 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06326411
The ClinicalTrials.gov registry entry for NCT06326411 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nested Therapeutics, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 9 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention — of which NST-628 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06326411 reports 20 study locations spanning 12 distinct geographic areas — top geographies include New York, Texas, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06326411 about?
NCT06326411 is a clinical study titled "A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors". This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment optio...
What is the current status of trial NCT06326411?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 230 participants. The study started on 2024-04-09. Estimated completion is 2029-11.
What conditions does trial NCT06326411 study?
This clinical trial studies the following conditions: Melanoma, Glioma, Solid Tumor, Adult, NSCLC, Oncology. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06326411?
The interventions under investigation include: NST-628 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06326411?
This trial is sponsored by Nested Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06326411 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.